Tremor and β 2-adrenergic agents: Is it a real clinical problem?

Pulmonary Pharmacology and Therapeutics

Volumn 25, Issue 1, 2012, Pages 4-10

  Cazzola, Mario ^a,b   Matera, Maria Gabriella ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

2 Adrenergic agents; Devices; Hypokalaemia; Tolerance; Tremor

Indexed keywords

ADENYLATE CYCLASE; ADRENALIN; ARFORMOTEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR; CORTICOSTEROID; FENOTEROL; FORMOTEROL; INDACATEROL; ISOPRENALINE; POTASSIUM; PROPRANOLOL; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE;

AIRWAY RESISTANCE; ASTHMA; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOWN REGULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; FORCED EXPIRATORY VOLUME; HAND TREMOR; HEART OUTPUT; HUMAN; HYPOKALEMIA; INFLAMMATORY CELL; LUNG ALVEOLUS CELL; MAXIMUM PLASMA CONCENTRATION; MEMBRANE PERMEABILITY; METERED DOSE INHALER; MUSCLE ACTION POTENTIAL; MUSCLE CONTRACTION; MUSCLE FORCE; MUSCLE SPINDLE; MUSCLE TETANIC CONTRACTION; NEBULIZATION; NONHUMAN; POSTURAL TREMOR; POTASSIUM BLOOD LEVEL; POTASSIUM TRANSPORT; POWDER INHALER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTING TREMOR; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TREMOR;

ADMINISTRATION, ORAL; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AEROSOLS; BRONCHODILATOR AGENTS; DRUG TOLERANCE; HUMANS; TREMOR;

EID: 84856797588     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2011.12.004     Document Type: Review

References (101)

1. Ahrens R.C. Skeletal muscle tremor and the influence of adrenergic drugs. JAsthma 1990, 27:11-20.
2. Young R.R. Pathophysiology and pharmacology of tremors. Electromyography in CNS disorders 1984, 143-159. Butterworth, Boston. B.T. Shahani (Ed.).
3. Bhidayasiri R. Differential diagnosis of common tremor syndromes. Postgrad Med J 2005, 81:756-762.
4. Jankovic J., Fahn S. Physiologic and pathologic tremors: diagnosis, mechanism and management. Ann Intern Med 1980, 93:460-465.
5. Fellows I.W., Macdonald I.A., Wharrad H.J., Birmingham A.T. Low plasma concentrations of adrenaline and physiological tremor in man. JNeurol Neurosurg Psychiatry 1986, 49:396-399.
6. Birmingham A.T., Wharrad H.J., Williams E.J. The variation of finger tremor with age in man. JNeurol Neurosurg Psychiatry 1985, 48:788-798.
7. Morrison S., Newell K.M. Postural and resting tremor in the upper limb. Clin Neurophysiol 2000, 111:651-663.
8. Barbosa M.T., Caramelli P., Maia D.P., Cunningham M.C., Guerra H.L., Lima-Costa M.F., et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambui study). Mov Disord 2006, 21:800-808.
9. Benito-León J., Bermejo-Pareja F., Morales J.M., Vega S., Molina J.A. Prevalence of essential tremor in three elderly populations of central Spain. Mov Disord 2003, 18:389-394.
10. Thanvi B., Lo N., Robinson T. Essential tremor - the most common movement disorder in older people. Age Ageing 2006, 35:344-349.
11. Stolze H., Petersen G., Raethjen J., Wenzelburger R., Deuschl G. The gait disorder of advanced essential tremor. Brain 2001, 124:2278-2286.
12. Wenning G.K., Kiechl S., Seppi K., Müller J., Högl B., Saletu M., et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005, 4:815-820.
13. 2-Adrenoceptor agonists: current and future direction. Br J Pharmacol 2011, 163:4-17.
14. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998, 158:S146-S153.
15. 2-agonists prevent Th1 development by selective inhibition of interleukin 12. JClin Invest 1997, 100:1513-1519.
16. Agarwal S.K., Marshall G.D. β-adrenergic modulation of human type-1/type-2 cytokine balance. JAllergy Clin Immunol 2000, 105:91-98.
17. Lai C.K., Twentyman O.P., Holgate S.T. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am Rev Respir Dis 1989, 140:917-923.
18. 2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001, 285:2583-2593.
19. Taylor D.R. The β-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med 2009, 179:976-978.
20. Connacher A.A., Bennet W.M., Jung R.T. Clinical studies with the β-adrenergic receptor agonist BRL-26830A. Am J Clin Nutr 1992, 55:258S-261S.
21. Tinkelman D.G., DeLong R., Lutz C., Spangler D.L. Evaluation of tremor activity and efficacy of oral procaterol in adult patients with asthma. JAllergy Clin Immunol 1990, 85:719-728.
22. Nizet T.A., Broeders M.E., Folgering H.T. Tremor side effects of salbutamol, quantified by a laser pointer technique. Respir Med 2004, 98:844-850.
23. Shrewsbury S., Hallett C. Salmeterol 100μg: an analysis of its tolerability in single and chronic-dose studies. Ann Allergy Asthma Immunol 2001, 87:465-473.
24. 2-agonists for acute bronchitis. Cochrane Database Syst Rev 2001, 1:CD001726.
25. Thiringer G., Svedmyr N. Evaluation of skeletal muscle tremor due to bronchodilator agents. Stand J Respir Dis 1975, 56:93-102.
26. van den Berg W., Fokkens J., Leferink J.G., Kreukniet J., Maes R.A., Bruynzeel P.L. Tremor measurement in asthma. Eur J Respir Dis 1982, 65:392-398.
27. Jenne J.W., Ridley D.J., Marcucci R.A., Druz W.S., Rook J.C. Objective and subjective tremor responses to oral beta-2 agents on first exposure. Am Rev Respir Dis 1982, 126:607-610.
28. Jenne J.W., Valcarenghi G., Druz W.S., Starkey P.W., Yu C., Shaughnessy P.K. Comparison of tremor responses to orally administered albuterol and terbutaline. Am Rev Respir Dis 1986, 134:708-711.
29. Newnham D.M., Lipworth B.J. Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system (" Ventstream" ). Thorax 1994, 49:762-770.
30. Mann R.D., Kubota K., Pearce G., Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. JClin Epidemiol 1996, 49:247-250.
31. Wilson J.W., Kunkle E.C. Epinephrine tremor: an experimental study. Trans Am Neurol Assn 1953, 78:282-284.
32. Marsden C.D., Foley T.H., Owen D.A.L., McAllister R.G. Peripheral β-adrenergic receptors concerned with tremor. Clin Sci 1967, 33:53-65.
33. Bowman W.C., Nott M.W. Actions of some sympathomimetic bronchodilator and beta-adrenoceptor blocking drugs on contractions of the cat soleus muscle. Br J Pharmacol 1970, 38:37-49.
34. Holmberg E., Waldeck B. On the possible role of potassium ions in the action of terbutaline on skeletal muscle contractions. Acta Pharmacol Toxicol 1980, 46:141-149.
35. Bowman W.C. Effects of adrenergic activators and inhibitors on the skeletal muscles. Handbook of experimental pharmacology 1980, vol. 54/2. Springer-Verlag, Berlin. L. Szekeres (Ed.).
36. Freedman B.J. Trial of new bronchodilator, terbutaline, in asthma. Br Med J 1971, 1:633-636.
37. 2-adrenergic stimulant drugs in bronchial asthma. Br Med J 1971, 1:637-639.
38. Watson J.M., Richens A. The effects of salbutamol and terbutaline on physiological tremor, bronchial tone and heart rate. Br J Clin Pharmac 1974, 1:223-227.
39. Rodrigo G., Rodrigo C. Effect of age on bronchodilator response in acute severe asthma treatment. Chest 1997, 112:19-23.
40. Morgan J.C., Sethi K.D. Drug-induced tremors. Lancet Neurol 2005, 4:866-876.
41. Gleiter C.H. Fenoterol: pharmacology and clinical use. Cardiovascular Drug Rev 1999, 17:87-116.
42. Newhouse M.T., Dolovich M.B., Kazim F. Dose-effect relationship of the β-agonists fenoterol and salbutamol in patients with asthma. Chest 1994, 105:1738-1742.
43. Whale C.I., Sovani M.P., Mortimer K.J., Harrison T.W., Tattersfield A.E. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study. Br J Clin Pharmacol 2008, 65:841-847.
44. 2-agonists. Eur J Clin Pharmacol 2002, 58:S1-S67.
45. Lötvall J., Ankerst J. Long duration of airway but not systemic effects of inhaled formoterol in asthmatic patients. Respir Med 2008, 102:449-456.
46. Pauwels R.A., Sears M.R., Campbell M., Villasante C., Huang S., Lindh A., et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003, 22:787-794.
47. Smyth E.T., Pavord I.D., Wong C.S., Wisniewski A.F., Williams J., Tattersfield A.E. Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma. BMJ 1993, 306:543-545.
48. Lötvall J., Lunde H., Svedmyr N. Onset of bronchodilation and finger tremor induced by salmeterol and salbutamol in asthmatic patients. Can Respir J 1998, 5:191-194.
49. Palmqvist M., Ibsen T., Mellén A., Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999, 160:244-249.
50. 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Thorax 1996, 51:54-58.
51. Donohue J.F., Hanania N.A., Sciarappa K.A., Goodwin E., Grogan D.R., Baumgartner R.A., et al. Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis 2008, 2:37-48.
52. Richter K., Hartmann U., Metzenauer P., Magnussen H. Randomised trial comparing as-needed versus regular treatment with formoterol in patients with persistent asthma. Respir Med 2007, 101:467-475.
53. Moen M.D. Indacaterol: in Chronic obstructive pulmonary disease. Drugs 2010, 70:2269-2280.
54. Bowman W.C., Rodger I.W. Actions of the sympathomimetic bronchodilator, rimiterol (R798) on the cardiovascular, respiratory and skeletal muscle systems of the anaesthetized cat. Br J Pharmacol 1972, 45:574-583.
55. 2-adrenoceptors. Scand J Resp Dis 1977, 58:5-10.
56. Perucca E., Pickles H., Richens A. Effect of atenolol, metoprolol and propranolol on isoproterenol induced tremor and tachycardia in normal subjects. Clin Pharmac Ther 1981, 29:425-433.
57. Rodger IW, Bowman WC. Adrenoceptors in skeletal muscle. In Adrenoceptors and catecholamine action - part B. Kunos G ed, John Wiley & Sons, New York 1983, pp. 123-155.
58. Foley T.H., Marsden C.D., Owen D.A. Evidence for a direct peripheral effect of adrenaline on physiological tremor in man. JPhysiol 1967, 189:65P-66P.
59. Abila B., Lazarus J.H., Kingswood J.C., Marshall R.W., Wilson J.F., Richens A. Tremor: an alternative approach for investigating adrenergic mechanisms in thyrotoxicosis. Clin Sci (Lond) 1985, 69:459-463.
60. Waldeck B. An invitro method for the study of β-receptor mediated effects on slow contracting skeletal muscle. JPharm Pharmacol 1976, 28:434-436.
61. Tesfamariam B., Waldron T., Seymour A.A. Quantitation of tremor in response to β-adrenergic receptor stimulation in primates: relationship with hypokalemia. JPharmacol Toxicol Meth 1998, 40:201-205.
62. Lakie M., Hayes N.R., Combes N., Langford N. Is postural tremor size controlled by interstitial potassium concentration in muscle?. JNeurol Neurosurg Psychiatry 2004, 75:1013-1018.
63. Shrewsbury S., Hallett C. Salmeterol 100microg: an analysis of its tolerability in single- and chronic-dose studies. Ann Allergy Asthma Immunol 2001, 87:465-473.
64. Vathenen A.S., Britton J.R., Ebden P., Cookson J.B., Wharrad H.J., Tattersfield A.E. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988, 138:850-855.
65. Wong C.S., Pavord I.D., Williams J., Britton J.R., Tattersfield A.E. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990, 336:1396-1399.
66. Maconochie J.G., Forster J.K. Dose-response study with high-dose inhaled salmeterol in healthy subjects. Br J Clin Pharmacol 1992, 33:342-345.
67. 2-adrenoceptor-mediated responses to inhaled salbutamol. Br J Clin Pharmacol 2001, 51:359-362.
68. Hochhaus G., Schmidt E., Rominger K.L., Möllmann H. Pharmacokinetic/dynamic correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration. Pharm Res 1992, 9:291-297.
69. Taburet A.-M., Schmit B. Pharmacokinetic optimisation of asthma treatment. Clin Pharmacokinet 1994, 26:396-418.
70. Clark D.J., Lipworth B.J. Dose-response of inhaled drugs in asthma. An update. Clin Pharmacokinet 1997, 32:58-74.
71. Rodrigo G., Rodrigo C. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels. Am J Emerg Med 1996, 14:144-150.
72. Cazzola M., Testi R., Matera M.G. Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet 2002, 41:19-30.
73. 2-receptors in the human heart. Circulation Res 1989, 65:546-553.
74. Arnold J.M., McDevitt D.G. Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propanolol, practolol and atropine. Br J Clin Pharmacol 1983, 16:175-184.
75. Lönnerholm G., Foucard T., Lindstram B. Dose, plasma concentration, and effect of oral terbutaline in long-term treatment of childhood asthma. JAllergy Clin Immunol 1984, 73:508-515.
76. Rodrigo C., Rodrigo G. Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer. Am J Emerg Med 1998, 16:637-642.
77. Newman S.P., Hirst P.H., Pitcairn G.R., Clark A.R. Understanding regional lung deposition data in gamma scintigraphy. Respiratory drug delivery VI 1998, 9-16. Interpharm, Buffalo Grove. R.N. Dalby, P.R. Byron, S.J. Farr (Eds.).
78. Sangwan S., Agosti J.M., Bauer L.A., Otulana B.A., Morishige R.J., Cipolla D.C., et al. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. JAerosol Med 2001, 14:185-195.
79. Esposito-Festen J.E., Zanen P., Tiddens H.A., Lammers J.W. Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. Br J Clin Pharmacol 2007, 64:328-334.
80. Scalabrin D.M., Naspitz C.K. Efficacy and side effects of salbutamol in acute asthma in children: comparison of oral route and two different nebulizer systems. JAsthma 1993, 30:51-59.
81. Vangveeravong M. JMed Assoc Thai. Acomparative study of efficacy of salbutamol via metered dose inhaler with volumatic spacer and via dry powder inhaler, easyhaler, to nebulization in mild to moderate severity acute asthma exacerbation in childhood 2008, 91(Suppl. 3):S115-S123.
82. Persson G., Gruvstad E., Ståhl E. Anew multiple dose powder inhaler, (Turbuhaler), compared with a pressurized inhaler in a study of terbutaline in asthmatics. Eur Respir J 1988, 1:681-684.
83. Bauer K.G., Kaik B., Sertl K., Kaik G.A. Studies on the bronchodilator, tremorogenic, cardiovascular and hypokalaemic effects of fenoterol dry powder in asthma. Br J Clin Pharmacol 1993, 36:285-292.
84. Randell J., Saarinen A., Walamies M., Vahteristo M., Silvasti M., Lähelmä S. Safety of formoterol after cumulative dosing via easyhaler and aerolizer. Respir Med 2005, 99:1485-1493.
85. Bauer K., Sertl K., Kaik B., Kaik G. Effect of solution and suspension type aerosol of formoterol on tremor response and airways in patients with asthma. JAllergy Clin Immunol 1995, 96:495-501.
86. Lipworth B.J., Clark D.J. Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer. Br J Clin Pharmacol 1998, 45:160-163.
87. Cates C. Spacers and nebulisers for the delivery of beta-agonists in non-life-threatening acute asthma. Respir Med 2003, 97:762-769.
88. Johnson M. The β-adrenoceptor. Am J Respir Crit Care Med 1998, 158:S146-S153.
89. Rothwell N.J., Stock M.J., Sudera D.K. Changes in tissue blood flow and beta-receptor density of skeletal muscle in rats treated with the beta2-adrenoceptor agonist clenbuterol. Br J Pharmacol 1987, 90:601-607.
90. Elfellah M.S., Reid J.L. Regulation of β-adrenoceptors in the guinea pig left ventricle and skeletal muscle following chronic agonist treatment. Eur J Pharmac 1990, 182:387-392.
91. 2-adrenoceptor density in female rats. Naunyn-Schmiedeberg's Arch Pharmacol 1991, 344:449-453.
92. Lipworth B.J., Struthers A.D., McDevitt D.G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis 1989, 140:586-592.
93. Svedmyr N.L., Larsson S.A., Thiringer G.K. Development of " resistance" in beta-adrenergic receptors of asthmatic patients. Chest 1976, 69:479-483.
94. Maconochie J.G., Minton N.A., Chilton J.E., Keene O.N. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol?. Br J Clin Pharmacol 1994, 37:199-204.
95. Lötvall J., Lunde H., Ullman A., Törnqvist H., Svedmyr N. Twelve months, treatment with inhaled salmeterol in asthmatic patients. Effects on beta 2-receptor function and inflammatory cells. Allergy 1992, 47:477-483.
96. 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 1995, 50:497-504.
97. 2-agonists and corticosteroids: new developments and controversies. Report of a meeting in November 1990. Am Rev Respir Dis 1992, 146:1637-1641.
98. 2-adrenoceptor subsensitivity induced by regular formoterol. Chest 1998, 113:34-41.
99. Tan K.S., Grove A., McLean A., Gnosspelius Y., Hall I.P., Lipworth B.J. Systemic corticosteroid rapidly reverses bronchodilator subsensitivity induced by formoterol in asthmatic patients. Am J Respir Crit Care Med 1997, 156:28-35.
100. Gibson P.G., Powell H., Ducharme F.M. Differential effects of maintenance long-acting β-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. JAllergy Clin Immunol 2007, 119:344-350.
101. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010, 4:CD005533.